Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GFH 375

Next Previous
Drug Profile

GFH 375

Alternative Names: GFH-375; GFH375/VS-7375; VS-7375

Latest Information Update: 28 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GenFleet Therapeutics
  • Developer GenFleet Therapeutics; Verastem Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Pancreatic cancer
  • Phase II Adenocarcinoma; Colorectal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 25 Aug 2026 GenFleet Therapeutics plans a phase-II trial for Pancreatic cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in China (Unspecified), (NCT07784374)
  • 27 Jul 2026 Phase-III clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT07668752)
  • 25 Jun 2026 Genfleet Therapeutics plans a phase III trial for Non-small cell lung cancer (Late stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in China (PO, Tablet) (NCT07668752)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top